Latest Ratios: P/E Ratio 52.1x · EV/EBITDA 14.7x · ROE 12.0%. (1997–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.9B | $2.6B | $3.2B | $4.4B | $4.3B | $3.2B | $5.7B | $5.2B | $4.6B | $3.9B | $2.1B |
| Enterprise Value | $5.8B | $3.5B | $4.1B | $5.0B | $4.7B | $3.8B | $6.3B | $5.5B | $4.8B | $4.0B | $2.3B |
| P/E Ratio → | 52.11 | 26.36 | 19.09 | 37.27 | 36.94 | 75.26 | 71.62 | 67.34 | 84.12 | 86.07 | — |
| P/S Ratio | 3.64 | 1.92 | 2.36 | 3.35 | 3.64 | 3.27 | 6.54 | 5.22 | 4.79 | 4.33 | 2.36 |
| P/B Ratio | 6.35 | 3.21 | 3.91 | 4.57 | 5.20 | 4.33 | 7.78 | 8.80 | 6.93 | 5.20 | 2.83 |
| P/FCF | 18.64 | 9.83 | 22.50 | 38.00 | 26.13 | 42.86 | 79.34 | 47.18 | 114.87 | 26.89 | 25.00 |
| P/OCF | 16.56 | 8.73 | 17.64 | 24.14 | 15.58 | 18.85 | 52.33 | 32.64 | 29.08 | 17.76 | 13.09 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.65 | 3.03 | 3.83 | 4.05 | 3.79 | 7.21 | 5.53 | 4.97 | 4.41 | 2.56 |
| EV / EBITDA | 14.69 | 8.91 | 12.47 | 19.79 | 19.67 | 22.52 | 36.08 | 27.97 | 24.94 | 27.42 | 35.04 |
| EV / EBIT | 24.17 | 22.57 | 16.69 | 24.25 | 28.33 | 35.83 | 62.74 | 32.99 | 57.60 | 62.15 | 57.77 |
| EV / FCF | — | 13.59 | 28.95 | 43.44 | 29.08 | 49.74 | 87.51 | 49.96 | 119.35 | 27.40 | 27.10 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.7% | 55.7% | 57.2% | 54.4% | 53.3% | 53.4% | 49.2% | 49.4% | 43.2% | 45.6% | 42.7% |
| Operating Margin | 18.1% | 18.1% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% | 6.2% | -2.2% |
| Net Profit Margin | 7.3% | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | -3.0% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.0% | 12.0% | 18.8% | 13.2% | 14.7% | 5.9% | 12.1% | 12.2% | 7.7% | 6.1% | -3.6% |
| ROA | 4.0% | 4.0% | 7.2% | 5.7% | 6.1% | 2.4% | 5.1% | 6.0% | 4.4% | 3.7% | -2.1% |
| ROIC | 10.3% | 10.3% | 10.0% | 8.6% | 9.1% | 4.7% | 6.1% | 8.9% | 7.5% | 4.8% | -1.5% |
| ROCE | 12.1% | 12.1% | 11.8% | 9.2% | 10.1% | 5.4% | 7.0% | 10.2% | 8.8% | 6.0% | -1.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.54 | 1.54 | 1.49 | 0.84 | 0.94 | 1.04 | 1.06 | 0.75 | 0.52 | 0.34 | 0.43 |
| Debt / EBITDA | 3.08 | 3.08 | 3.70 | 3.19 | 3.18 | 4.67 | 4.47 | 2.26 | 1.81 | 1.74 | 4.87 |
| Net Debt / Equity | — | 1.23 | 1.12 | 0.66 | 0.59 | 0.70 | 0.80 | 0.52 | 0.27 | 0.10 | 0.24 |
| Net Debt / EBITDA | 2.47 | 2.47 | 2.78 | 2.48 | 2.00 | 3.12 | 3.37 | 1.56 | 0.94 | 0.51 | 2.71 |
| Debt / FCF | — | 3.76 | 6.44 | 5.45 | 2.96 | 6.88 | 8.17 | 2.78 | 4.48 | 0.51 | 2.09 |
| Interest Coverage | 5.46 | 5.46 | 25.35 | 15.89 | 11.43 | 6.14 | 5.95 | 10.23 | 8.43 | 14.18 | 4.84 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.95 | 2.95 | 1.62 | 2.56 | 3.06 | 1.71 | 2.74 | 2.20 | 2.44 | 1.35 | 2.42 |
| Quick Ratio | 1.87 | 1.87 | 0.99 | 1.50 | 2.03 | 1.05 | 1.46 | 1.21 | 1.62 | 0.94 | 1.58 |
| Cash Ratio | 0.87 | 0.87 | 0.53 | 0.60 | 1.13 | 0.59 | 0.76 | 0.50 | 0.72 | 0.47 | 0.66 |
| Asset Turnover | — | 0.56 | 0.56 | 0.60 | 0.60 | 0.53 | 0.48 | 0.78 | 0.76 | 0.73 | 0.72 |
| Inventory Turnover | 1.93 | 1.93 | 1.59 | 1.88 | 2.10 | 1.58 | 1.37 | 1.85 | 2.83 | 3.06 | 2.87 |
| Days Sales Outstanding | — | 59.33 | 54.36 | 57.60 | 55.95 | 58.57 | 53.49 | 61.00 | 69.80 | 61.06 | 62.89 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 3.8% | 5.2% | 2.7% | 2.7% | 1.3% | 1.4% | 1.5% | 1.2% | 1.2% | — |
| FCF Yield | 5.4% | 10.2% | 4.4% | 2.6% | 3.8% | 2.3% | 1.3% | 2.1% | 0.9% | 3.7% | 4.0% |
| Buyback Yield | 3.6% | 6.8% | 7.0% | 0.0% | 1.8% | 0.0% | 0.0% | 3.4% | 3.5% | 2.6% | 0.0% |
| Total Shareholder Yield | 3.6% | 6.8% | 7.0% | 0.0% | 1.8% | 0.0% | 0.0% | 3.4% | 3.5% | 2.6% | 0.0% |
| Shares Outstanding | — | $47M | $51M | $51M | $51M | $51M | $51M | $52M | $53M | $54M | $52M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HAE stock.
Haemonetics Corporation's current P/E ratio is 52.1x. The historical average is 45.1x. This places it at the 70th percentile of its historical range.
Haemonetics Corporation's current EV/EBITDA is 14.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.4x.
Haemonetics Corporation's return on equity (ROE) is 12.0%. The historical average is 8.7%.
Based on historical data, Haemonetics Corporation is trading at a P/E of 52.1x. This is at the 70th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Haemonetics Corporation has 55.7% gross margin and 18.1% operating margin. Operating margin between 10-20% is typical for established companies.
Haemonetics Corporation's Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Persistent TTM revenue decline
Metrics are mathematically derived from official filings.
Margin Recovery Masks Underlying Volatility
Gross margin expanded to 59.8% in Q1 FY2027 from 53.3% a year earlier, yet net margin swung from -5.8% to 9.7% sequentially, per reported financials, indicating earnings quality remains uneven.
The gross margin improvement suggests pricing power and cost control in production, but the wide swings in net margin—from -5.8% in Q4 FY2026 to 9.7% in Q1 FY2027—point to non-operating items or one-time charges distorting bottom-line profitability. Operating margin at 16.9% in Q1 FY2027 is the highest in five quarters, yet SG&A remains elevated at 35% of revenue, implying that margin expansion is not yet broad-based. Investors should monitor whether the gross margin gains can be sustained as input costs and product mix evolve.
Return on Capital Remains Subdued
ROIC has hovered between 1.4% and 2.9% over the past ten quarters, with Q1 FY2027 at 2.4%, according to quarterly data, suggesting the company is not yet compounding returns on invested capital at an attractive rate.
Despite a strong gross margin, ROIC remains low, indicating that the capital base—bolstered by acquisitions and placed equipment—is not generating commensurate operating profits. The slight uptick from 1.4% in 2024Q4 to 2.4% in Q1 FY2027 is encouraging but still below the cost of capital, implying value creation is limited. The driver appears to be asset efficiency, as asset turnover has been flat at 0.14, rather than margin expansion, which suggests that the business model requires heavy asset investment to generate sales.
Working Capital Cycle Lengthens on Inventory
Cash conversion cycle extended to 227 days in Q1 FY2027 from 202 days in 2024Q4, driven by inventory days rising to 204, as per quarterly data, indicating growing working capital absorption.
The lengthening CCC is primarily due to a sharp increase in days inventory outstanding (DIO) from 185 to 204 over the same period, while days sales outstanding (DSO) remained stable around 56-58 days. This suggests that inventory is building, possibly in anticipation of demand or due to supply chain issues, which ties up cash and reduces efficiency. The company's ability to manage inventory levels will be critical, as prolonged high DIO could pressure free cash flow and signal demand softness.
Leverage Creeps Higher on Acquisition Debt
Debt-to-equity rose from 0.84 in 2024Q4 to 1.40 in Q1 FY2027, with interest coverage at 4.81, per balance sheet data, indicating increased financial risk but still manageable debt service.
The rise in leverage is likely tied to the OpSens acquisition, as total debt increased to $1.2B while equity remained relatively stable. Interest coverage of 4.81 in Q1 FY2027 is adequate but down from 8.55 in 2025Q2, reflecting higher debt and volatile operating income. The negative interest coverage in Q4 FY2026 (-4.28) highlights the risk of earnings volatility, but the current quarter's recovery suggests the company can service its debt under normal conditions. Investors should monitor whether cash flow generation can keep pace with debt obligations, especially if growth initiatives require further capital.
Liquidity Buffer Strengthens but Inventory Heavy
Current ratio improved to 3.08 in Q1 FY2027 from 2.56 in 2024Q4, while quick ratio rose to 1.91, per quarterly data, indicating a solid short-term liquidity position despite inventory build.
The current ratio of 3.08 suggests ample coverage of short-term liabilities, but the quick ratio of 1.91 indicates that a significant portion of current assets is tied up in inventory, which may be less liquid in a downturn. The improvement in liquidity ratios is partly due to a rise in cash to $223.4M, but the inventory build (DIO at 204 days) could become a drag if demand falters. Under severe stress, the company appears able to meet obligations, but the reliance on inventory conversion warrants monitoring.
Misapplied Metric: P/E on Volatile Earnings
The trailing P/E of 44.29 is misleading given net margin swings from -5.8% to 17.5% over the past year, as per reported figures, so investors should focus on EV/EBITDA or normalized earnings.
The P/E ratio is distorted by the volatile net income, which swung from a loss in Q4 FY2026 to a profit in Q1 FY2027, making the trailing multiple unreliable. EV/EBITDA of 12.86 provides a more stable valuation metric, as it is less affected by non-operating items and tax adjustments. Additionally, the company's razor-and-blade model with placed equipment and software subscriptions suggests that free cash flow or EBITDA may better reflect underlying earning power than net income. Investors should adjust for one-time items and the impact of acquisitions to derive a normalized earnings figure for valuation.